1. Acalabrutinib for adults with mantle cell lymphoma. Issue 3 (4th March 2019) Authors: Jurczak, Wojciech; Długosz-Danecka, Monika; Wang, Michael Journal: Expert review of clinical pharmacology Issue: Volume 12:Issue 3(2019) Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Issue 10121 (17th February 2018) Authors: Wang, Michael; Rule, Simon; Zinzani, Pier Luigi; Goy, Andre; Casasnovas, Olivier; Smith, Stephen D; Damaj, Gandhi; Doorduijn, Jeanette; Lamy, Thierry; Morschhauser, Franck; Panizo, Carlos; Shah, Bijal; Davies, Andrew; Eek, Richard; Dupuis, Jehan; Jacobsen, Eric; Kater, Arnon P; Le Gouill, Steven;... Journal: Lancet Issue: Volume 391:Issue 10121(2018) Page Start: 659 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Issue 31 (1st November 2021) Authors: Byrd, John C.; Hillmen, Peter; Ghia, Paolo; Kater, Arnon P.; Chanan-Khan, Asher; Furman, Richard R.; O'Brien, Susan; Yenerel, Mustafa Nuri; Illés, Arpad; Kay, Neil; Garcia-Marco, Jose A.; Mato, Anthony; Pinilla-Ibarz, Javier; Seymour, John F.; Lepretre, Stephane; Stilgenbauer, Stephan; Robak, Tad... Journal: Journal of clinical oncology Issue: Volume 39:Issue 31(2021) Page Start: 3441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. Issue 12 (14th December 2022) Authors: Ghia, Paolo; Pluta, Andrzej; Wach, Małgorzata; Lysak, Daniel; Šimkovič, Martin; Kriachok, Iryna; Illés, Árpád; de la Serna, Javier; Dolan, Sean; Campbell, Philip; Musuraca, Gerardo; Jacob, Abraham; Avery, Eric J.; Lee, Jae Hoon; Usenko, Ganna; Wang, Min Hui; Yu, Ting; Jurczak, Wojciech Journal: HemaSphere Issue: Volume 6:Issue 12(2022) Page Start: e801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Issue 10232 (18th April 2020) Authors: Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Pao... Journal: Lancet Issue: Volume 395:Issue 10232(2020) Page Start: 1278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Issue 5 (16th April 2021) Authors: Ghia, Paolo; Dlugosz-Danecka, Monika; Scarfò, Lydia; Jurczak, Wojciech Journal: Leukemia & lymphoma Issue: Volume 62:Issue 5(2021) Page Start: 1066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. (15th May 2017) Authors: Szmit, Sebastian; Jurczak, Wojciech; Zaucha, Jan Maciej; Długosz-Danecka, Monika; Sosnowska-Pasiarska, Barbara; Chmielowska, Ewa; Joks, Monika; Drozd-Sokołowska, Joanna; Knopińska-Posłuszny, Wanda; Spychałowicz, Wojciech; Kumiega, Beata; Charliński, Grzegorz; Morawska, Marta; Słomian, Grzegorz Journal: International journal of cardiology Issue: Volume 235(2017) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cardio-oncology for better lymphoma therapy outcomes. Issue 4 (April 2020) Authors: Jurczak, Wojciech; Długosz-Danecka, Monika; Szmit, Sebastian Journal: Lancet Issue: Volume 7:Issue 4(2020) Page Start: e273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Characterization and treatment of immune thrombocytopenia in Europe: a qualitative observational study. Issue 1 (1st January 2021) Authors: Pogna, Edgar A.; Middleton, Simon; Nazir, Jameel; Ralph, Leah; Wilson, Koo; Jurczak, Wojciech Journal: Hematology Issue: Volume 26:Issue 1(2021) Page Start: 860 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Issue 3 (4th March 2018) Authors: Jurczak, Wojciech; Ramanathan, Sundra; Giri, Pratyush; Romano, Alessandra; Mocikova, Heidi; Clancy, Jill; Lechuga, Mariajose; Casey, Michelle; Boni, Joseph; Giza, Agnieszka; Hess, Georg Journal: Leukemia & lymphoma Issue: Volume 59:Issue 3(2018) Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗